Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shortlist Revealed For 2024 GGB Awards

Finalists Named With Winners To Be Announced At 9 October Ceremony In Milan

Executive Summary

The final shortlist of entries across all 14 categories of the Global Generics & Biosimilars Awards 2024 has now been revealed, ahead of our prizegiving ceremony in Milan on 9 October.

The final shortlist of entries has now been published for the Global Generics & Biosimilars Awards 2024, ahead of the winners being revealed at our ceremony in Milan on 9 October. Click here to see the full details.

Covering activities undertaken between 1 September 2023 and 31 July 2024, the entries have been evaluated by our panel of independent expert judges to compile the shortlist of finalists. A prizegiving ceremony announcing the winners will then take place at the Hotel NH Milano Fiera on Wednesday 9 October, during CPhI Worldwide week.

Dave Wallace, executive editor of Generics Bulletin, said “We’re delighted to announce such a high-quality shortlist for the Global Generics and Biosimilars Awards 2024, reflecting the ongoing contributions made by the off-patent pharmaceutical industry worldwide.”

“This year saw the usual large number of excellent entries covering numerous impressive achievements, and our judging panel has had a very difficult job in narrowing them down to these select finalists. I’d like to thank the judges for volunteering their time and expertise, as well as all those companies that entered. Congratulations to all of this year’s finalists, and we look forward to celebrating the winners in a month’s time in Milan.”

For more details on the event, Generics Bulletin’s editors recorded a podcast talking about the benefits of attending the awards – which remains free of charge – as well as exploring the reasons why off-patent industry players might want to be involved with the event (see sidebar).

Backed by our headline sponsor IQVIA, category sponsors for the awards also include Adalvo in the Active Pharmaceutical Ingredient supplier of the Year category, Aurobindo for Industry Partner of the Year, Cerba Research for Company of the Year – Americas, as well as Pharmacloud for our Leader of the Year category.

The awards are also supported by International Health Partners in our corporate social responsibility initiative of the year category. Our 2024 supporters also include the International Generic and Biosimilars Medicines Association, as well as the US Association for Accessible Medicines and its Biosimilars Council.

Other categories will include our company of the year award and our two other regional company of the year awards for the Asia-Pacific and EMEA regions; acquisition of the year; biosimilar initiative of the year; and business development of the year.

Meanwhile, further awards will recognize the best campaign of the year; regulatory achievement of the year; and value added medicine initiative of the year.

For a full list of the awards categories, how to attend and other information, go here.

To enquire about sponsorship opportunities, please e-mail [email protected]

And to register interest in attending the Global Generics & Biosimilars Awards 2024, to receive the latest updates and for any further details, please e-mail [email protected]

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153759

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel